© Copyright 2012 Oregon State University. All Rights Reserved

Drug Use Research & Management Program
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, December 3, 2026 1:00 - 5:00 PM
Remote Meeting via Zoom Platform
MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

1:00 PM	A. Roll Call & Introductions	R. Citron (OSU)
	B. Conflict of Interest Declaration	R. Citron (OSU)
	C. Approval of Agenda and Minutes	R. Citron (OSU)
	D. Department Update	A. Gibler (OHA)
	E. Mental Health Clinical Advisory Group Update	A. Gibler (OHA)
1:20 PM	II. CONSENT AGENDA TOPICS	(Chair)

A. Oncology Prior Authorization Updates
B. Literature Scans
   1. Overactive Bladder Drugs
   2. Benign Prostate Hypertrophy Drugs
   3. Prenatal Vitamins, Oral
   4. B-vitamins, Oral
   5. Magnesium Replacement, Oral
      a. Public Comment

1:25 PM III. DUR ACTIVITIES

A. Quarterly Utilization Report	R. Citron (OSU)
B. ProDUR Report	L. Starkweather (Gainwell)
C. RetroDUR Report	D. Engen (OSU)
D. Oregon State Drug Review	K. Sentena (OSU)

   1. Efficacy and Safety of Newer Antipsychotic Combination Therapies
   2. West Coast Health Alliance: A New Approach to Regional Health Leadership

IV. NEW BUSINESS

1:40 PM	A. Literature Scans	
	1. Gout Agents/Prior Authorization Criteria	S. Servid (OSU)
	2. Hepatitis C Direct-Acting Antivirals/Prior Authorization Criteria	M. Herink (OSU) K. Sentena (OSU)
	3. Calcium/Vitamin D Replacement, Oral/Prior Authorization Criteria	
	4. Multivitamins, Oral/Prior Authorization Criteria	
	5. Spravato® (esketamine)/Safety Edit	
	6. Public Comment	
	7. Discussion and Clinical Recommendations to OHA	
1:55 PM	B. ADHD Class Update and New Drug Evaluation	D. Moretz (OSU)
	1. Simtriyo® (centanafadine) New Drug Evaluation	
	2. Class Update/Prior Authorization Criteria	
	3. Public Comment	
	4. Discussion and Clinical Recommendations to OHA	
2:10 PM	C. Newer and Conventional Antiemetics Class Update and New Drug Evaluation	K. Sentena (OSU)
	1. Nereus™ (tradipitant) New Drug Evaluation	
	2. Class Update/Prior Authorization Criteria	
	3. Public Comment	
	4. Discussion and Clinical Recommendations to OHA	
2:25 PM	D. Pregabalin Drug Use Evaluation	S. Servid (OSU)
	1. Drug Use Evaluation/Prior Authorization Criteria	
	2. Public Comment	
	3. Discussion and Clinical Recommendations to OHA	
2:40 PM	E. Topicals for Inflammatory Skin Disease	D. Moretz (OSU)
	1. Adquey™ (difamilat) New Drug Evaluation	
	2. Class Update/Prior Authorization Criteria	
	3. Public Comment	
	4. Discussion and Clinical Recommendations to OHA	
2:55 PM	BREAK	
3:10 PM	F. Biosimilar Policy Proposal	S. Servid (OSU)
	1. Policy Proposal/Prior Authorization Criteria	
	2. Public Comment	
	3. Discussion and Clinical Recommendations to OHA	
3:25 PM	G. Phosphodiesterase 5 Inhibitors Drug Use Evaluation	S. Servid (OSU)
	1. Drug Use Evaluation/Prior Authorization Criteria	
	2. Public Comment	
	3. Discussion and Clinical Recommendations to OHA	

3:35 PM	H. Insulin Pumps Prior Authorization Update 1. Prior Authorization Criteria 2. Public Comment 3. Discussion and Clinical Recommendations to OHA	S. Servid (OSU)
3:40 PM	I. Coronavirus Antivirals Class Update and New Drug Evaluation 1. Xocova® (ensitrelvir) New Drug Evaluation 2. Class Update/Prior Authorization Criteria 3. Public Comment 4. Discussion and Clinical Recommendations to OHA	D. Moretz (OSU)
3:50 PM	J. Genglycos™ (pariglasgene brecaparvovec-opnr) Orphan Drug Evaluation 1. Orphan Drug Evaluation/Prior Authorization Criteria 2. Public Comment 3. Discussion and Clinical Recommendations to OHA	D. Engen (OSU)
4:00 PM	V. OLD BUSINESS	
	A. Healthier Oregon Program Policy Updates 1. Diabetes, DPP-4 inhibitors B. Prioritized List Benefit Update Project Prior Authorization Criteria Updates	S. Servid (OSU)
4:10 PM	VI. EXECUTIVE SESSION	
4:50 PM	VII. RECONVENE for PUBLIC RECOMMENDATIONS	
	VIII. ADJOURN	